English | Español

Guardant Health
+ Technology/Innovation
Press release submission | May 31, 2020

GUARDANT: Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes